Last updated: October 29, 2026
Cathflo Activase is Genentech’s catheter-clearance formulation of alteplase, a recombinant tissue plasminogen activator. Its commercial position is mature rather than growth-driven. The product benefits from clinical familiarity, hospital protocols, and manufacturing complexity, but faces structural pressure from lower-cost alteplase products, hospital purchasing controls, supply interruptions, and the absence of a separately reported revenue line.
Cathflo’s financial trajectory cannot be calculated from Roche or Genentech public filings because sales are not disclosed as a standalone product. The available evidence supports a stable, strategically important hospital product with limited disclosed growth data and material exposure to generic or alternative alteplase supply.
What is Cathflo Activase and how is it used?
Cathflo Activase is alteplase for restoration of function in central venous access devices when withdrawal of blood is impaired or absent because of thrombotic occlusion. It is supplied as a sterile lyophilized powder that is reconstituted before use. The labeled dose is generally 2 mg in a 2 mL volume for patients weighing at least 30 kg, with a lower dose for patients below 30 kg. The solution is instilled into the catheter rather than administered as systemic thrombolytic therapy.[1]
Cathflo is distinct from systemic Activase products used for ischemic stroke, acute myocardial infarction and pulmonary embolism. The active ingredient is the same, but the indication, dose, administration route and hospital purchasing economics differ.
Cathflo Activase product profile
| Attribute |
Cathflo Activase |
| Active ingredient |
Alteplase |
| Drug class |
Recombinant tissue plasminogen activator |
| Manufacturer |
Genentech, a Roche company |
| FDA application |
Biologics license application |
| Primary use |
Restoration of catheter function |
| Dosage form |
Lyophilized injectable powder |
| Typical vial strength |
2 mg |
| Administration |
Intracatheter instillation |
| Commercial channel |
Hospitals, infusion centers, specialty care facilities |
| Market type |
Mature institutional biologic |
| Standalone revenue disclosure |
Not publicly reported |
The product’s value is linked to avoiding catheter replacement, treatment interruption and additional procedural costs. That economic value supports continued use even where lower-cost alternatives are available.
When did Cathflo Activase receive FDA approval?
The FDA approved Cathflo Activase in 2001 for restoration of function to central venous access devices after thrombotic occlusion.[1] The product followed the earlier development and approval of Activase for systemic thrombolytic indications.
FDA approval established a specific catheter-clearance indication for alteplase. That indication matters commercially because hospitals generally purchase and stock products according to labeled use, pharmacy-and-therapeutics committee decisions, reimbursement coding and institutional protocols.
Cathflo is regulated as a biologic rather than as a conventional small-molecule generic product. Any competitive product relying on a biosimilar or interchangeable-biologic pathway must satisfy the applicable Public Health Service Act requirements. An alteplase product may also compete through a separate application or alternative regulatory route, depending on its legal classification and FDA development strategy.
What is the patent and exclusivity status of Cathflo Activase?
Cathflo’s original regulatory exclusivity and core patent protection are long expired. The product was approved more than two decades ago, and the principal composition and recombinant tPA patent estate dates to the 1980s and 1990s.
Patent and exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Recombinant tPA patent activity |
1980s-1990s |
Established original molecule and manufacturing protection |
| Activase approval |
1987 |
Began systemic alteplase commercialization |
| Cathflo approval |
2001 |
Added catheter-clearance indication |
| Core patent expirations |
Primarily 2000s |
Removed core molecule barriers |
| Current period |
2020s |
Competition depends on regulatory approval, supply and contracting |
The remaining commercial protection is more likely to arise from manufacturing know-how, quality systems, process controls, product-specific regulatory history and hospital purchasing relationships than from a strong active-molecule patent barrier.
Are there active Cathflo formulation patents?
Cathflo’s formulation and presentation may have historically been supported by product-specific patents, process patents or regulatory exclusivity. The commercial relevance of any surviving patent depends on:
- The exact patent claims.
- Patent term adjustments or patent term extensions.
- Continuation or divisional applications.
- Whether the claims cover the marketed 2 mg vial, reconstitution method or manufacturing process.
- Whether a competing applicant must certify against the patent.
- Whether the patent is listed in the FDA’s Orange Book or is relevant to the biologics patent-dispute framework.
Publicly available product information does not establish a current, high-value patent blocking the entire alteplase catheter-clearance market. The age of the product makes a durable composition-of-matter barrier unlikely.
What is the Orange Book status of Cathflo Activase?
Cathflo is a biologic product, so its principal regulatory framework is the Purple Book and the Public Health Service Act rather than the conventional Orange Book framework used for abbreviated new drug applications.
The distinction affects generic-entry analysis. A competitor may not follow the ordinary small-molecule ANDA pathway if the reference product is regulated as a biologic. The relevant pathway may involve a biosimilar application under section 351(k), a full biologics license application, or another FDA route determined by the agency.
The FDA’s Purple Book and related biologics records are the more relevant sources for reference-product status, exclusivity periods and biosimilar competition. A conventional Orange Book patent listing should not be assumed merely because the product is sold as an injectable medicine.
How strong is the Cathflo Activase patent estate?
The patent estate is weak as a molecule-level barrier but stronger as an operational barrier.
Molecule-level protection
Alteplase is an old recombinant protein. Its foundational patent protection has expired. New entrants therefore do not face the same composition-of-matter barriers that protect newer biologics.
Formulation protection
Formulation claims can still matter if they cover a specific stability profile, excipient system, concentration, lyophilization process or reconstitution performance. Their practical value is limited if competitors can design around the claims while delivering an equivalent catheter-clearance product.
Manufacturing protection
Manufacturing is the more significant technical barrier. Alteplase production requires recombinant expression, purification, viral-safety controls, folding and activity control, sterility assurance and batch-to-batch consistency. A competitor must demonstrate comparable quality and clinical performance under the applicable FDA pathway.
Commercial protection
Cathflo has an established position in hospital protocols. That position creates switching costs that are not captured by patent expiration. Pharmacy committees may continue using the incumbent because of:
- Familiar dosing and handling.
- Existing electronic order sets.
- Nursing experience.
- Established efficacy and safety data.
- Contracting arrangements.
- Inventory integration.
- Risk aversion around central-line complications.
Which companies are challenging Cathflo Activase?
Competition comes from three categories: other alteplase products, alternative thrombolytics and non-drug catheter-management procedures.
| Competitive category |
Examples |
Competitive position |
| Alteplase products |
Generic or biosimilar alteplase candidates |
Most direct risk if FDA-approved for catheter clearance |
| Tenecteplase |
Modified tPA product |
Potential technical substitute, but not automatically interchangeable or approved for Cathflo’s indication |
| Urokinase |
Older thrombolytic option |
May be used in selected institutional settings |
| Mechanical clearance |
Catheter exchange, guidewire procedures, flushing protocols |
Competes when drug treatment is unsuccessful or unsuitable |
| Catheter replacement |
Procedural alternative |
Higher labor and intervention cost, but clinically available |
Tenecteplase is not automatically a Cathflo substitute. It has different pharmacology, dosing and approved uses. An institution would generally need a protocol, clinical justification and regulatory basis before replacing alteplase for catheter clearance.
What generic-entry risks exist for Cathflo Activase?
The most credible entry risk is a lower-priced alteplase product that obtains approval for the same catheter-clearance use or is adopted under institutional protocols for off-label use.
Generic and biosimilar entry scenarios
Scenario 1: Direct FDA-approved competitor
A competitor obtains FDA authorization for an alteplase product with catheter-clearance labeling. This would create the clearest substitution risk and could trigger formulary review, tender competition and price concessions.
Scenario 2: Alteplase product approved for another indication
A competing alteplase product enters the hospital market under a different indication. Hospitals may evaluate it for catheter use, but substitution would depend on institutional policy, clinical evidence, reimbursement and legal considerations.
Scenario 3: Biosimilar entry
A biosimilar applicant demonstrates high similarity to the reference alteplase product. Interchangeability would require a separate FDA determination. Without interchangeability, switching may remain controlled by clinicians and hospital formularies.
Scenario 4: Alternative thrombolytic adoption
Tenecteplase or urokinase gains use in catheter protocols. This would be a clinical and operational substitution threat, but not a conventional patent-driven generic launch.
Likely launch economics
Cathflo’s unit price can support competition, but the addressable market is specialized. A new entrant must pay for:
- Biologic development and comparability studies.
- Sterile manufacturing capacity.
- FDA regulatory work.
- Hospital contracting.
- Pharmacy and nursing education.
- Distribution and inventory support.
- Postmarketing surveillance.
The market may not justify aggressive standalone investment unless the entrant can use existing alteplase manufacturing, a broader thrombolytic portfolio or a large hospital sales infrastructure.
What is the FDA regulatory status of Cathflo Activase?
Cathflo remains an FDA-approved alteplase product for catheter clearance. The label includes warnings associated with bleeding risk, catheter-related complications and inappropriate administration. Because the drug is instilled into a catheter, the product is not equivalent in use to systemic alteplase dosing.[1]
The product’s mature regulatory status provides an advantage over newer entrants. Cathflo has a long history of labeled use, established preparation instructions and extensive real-world exposure. A competitor must demonstrate sufficient product quality and clinical reliability for a setting in which dosing errors or catheter complications can create immediate hospital risk.
What is known about Cathflo Activase revenue and financial trajectory?
Roche does not separately report Cathflo revenue in its public annual reports. Genentech’s product-level sales are generally aggregated within broader pharmaceutical categories, making a precise revenue series unavailable from public filings.[2][3]
The financial trajectory can therefore be assessed through market structure rather than reported product sales.
Revenue drivers
Cathflo revenue is supported by:
- The large installed base of central venous access devices.
- Continued use in oncology, critical care, dialysis and infusion settings.
- The cost of replacing occluded catheters.
- Protocol standardization.
- Product familiarity.
- Hospital demand for ready-to-use thrombolytic intervention.
Revenue pressures
Revenue faces pressure from:
- Hospital group purchasing organization negotiations.
- Public and private reimbursement controls.
- Competitor alteplase products.
- Supply shortages and allocation events.
- Catheter-management improvements.
- Reduced use of central venous devices in some care pathways.
- Price sensitivity among inpatient pharmacies.
Cathflo is unlikely to be a major growth asset within Roche’s overall pharmaceutical portfolio. Its role is closer to a mature cash-generating hospital product with strategic value in vascular-access care.
How do supply constraints affect Cathflo Activase?
Alteplase supply has periodically been affected by manufacturing disruptions, demand increases, production limitations and competing use across stroke, myocardial infarction, pulmonary embolism and catheter clearance. A shortage in systemic Activase can affect Cathflo availability because the same active pharmaceutical ingredient and related manufacturing capacity support multiple products.
During constrained supply periods, hospitals may:
- Restrict Cathflo use to high-priority cases.
- Substitute alternative thrombolytics.
- Use mechanical declotting procedures.
- Extend catheter replacement protocols.
- Allocate inventory by indication.
- Negotiate priority access with suppliers.
Supply resilience is therefore a material commercial advantage. A competitor with spare biologic manufacturing capacity could gain share quickly during an allocation event, even without a superior product.
What patent litigation affects Cathflo Activase?
No major current patent litigation is established in the public record as a central commercial constraint on Cathflo’s catheter-clearance business. The product’s foundational intellectual property is old, and the primary competitive issues are regulatory approval, manufacturing capacity, quality consistency and hospital contracting.
A future dispute could arise over:
- Biosimilar patent-listing procedures.
- Formulation claims.
- Lyophilization or reconstitution processes.
- Manufacturing methods.
- Labeling for catheter clearance.
- Substitution or interchangeability practices.
Litigation risk would be higher for a new entrant seeking a narrow Cathflo-specific label if Genentech asserted surviving formulation or process claims. The commercial impact would depend on whether the claims could block manufacture or only create a damages exposure.
What licensing deals are relevant to Cathflo Activase?
Cathflo is commercialized by Genentech within the Roche group. No major recent licensing transaction is publicly identified as changing ownership or control of the Cathflo franchise.
Potential licensing value would lie in:
- Regional commercialization rights.
- Alteplase manufacturing technology.
- Biosimilar development partnerships.
- Hospital-channel distribution.
- Alternative catheter-clearance formulations.
Because Cathflo is an established branded product, licensing would more likely concern geographic distribution or manufacturing than acquisition of a broad new patent estate.
How does Cathflo Activase compare with competing thrombolytics?
| Factor |
Cathflo Activase |
Tenecteplase |
Urokinase |
| Molecular type |
Recombinant alteplase |
Modified recombinant tPA |
Human urokinase |
| Cathflo-labeled catheter indication |
Yes |
Not automatically |
Depends on jurisdiction and protocol |
| Hospital familiarity |
High |
Increasing in other thrombolytic uses |
Variable |
| Patent position |
Mature and largely expired core rights |
Newer product-specific rights may exist |
Mature |
| Main advantage |
Established label and workflow |
Pharmacologic convenience in approved uses |
Alternative mechanism and availability |
| Main risk |
Price and supply competition |
Off-label or protocol limitations |
Lower familiarity and variable adoption |
Cathflo retains an advantage when hospitals prioritize labeled use and standardized catheter protocols. Its vulnerability rises when purchasing departments prioritize price or when supply interruptions force substitution.
What is the outlook for Cathflo Activase?
The base case is a mature, stable product with modest pricing pressure and episodic supply risk. Large organic growth is unlikely unless catheter utilization expands materially or the product gains broader use in new vascular-access protocols.
The strongest downside risks are:
- A reliable lower-cost alteplase competitor.
- A biosimilar with broad hospital contracting.
- Repeated supply interruptions.
- Replacement of drug declotting by mechanical or device-based approaches.
- Hospital protocols that favor alternative thrombolytics.
The strongest defenses are:
- Longstanding clinical adoption.
- FDA-labeled catheter-clearance use.
- Established hospital workflow.
- Manufacturing complexity.
- The cost and inconvenience of catheter replacement.
Key Takeaways
- Cathflo Activase is Genentech’s alteplase product for restoring function to thrombotically occluded central venous access devices.
- Its core molecule and original patent protection are mature; patent barriers are materially weaker than manufacturing and regulatory barriers.
- Cathflo is regulated as a biologic, making the Purple Book and Public Health Service Act more relevant than a conventional Orange Book analysis.
- Roche does not publicly disclose Cathflo revenue separately, so product-level revenue growth and margin estimates cannot be calculated from annual reports.
- The main competitive risks are lower-cost alteplase products, biosimilar-style entry, supply disruptions and alternative catheter-management procedures.
- Cathflo’s commercial value depends on hospital protocols, product familiarity, supply reliability and the avoided cost of catheter replacement.
- The most likely financial trajectory is stable-to-declining mature-product economics, with intermittent upside during competitor shortages and downside during successful hospital tender competition.
Frequently Asked Questions
Is Cathflo Activase the same drug as Activase?
Yes. Both contain alteplase, but Cathflo is labeled for intracatheter restoration of central venous access devices, while Activase is used systemically for thrombolytic indications.
Is Cathflo Activase interchangeable with tenecteplase?
No. Tenecteplase is a modified tPA product with different labeling, dosing and clinical characteristics. It is not automatically interchangeable with Cathflo.
Does Cathflo Activase have biosimilar competition?
The commercial risk exists, but a product would need applicable FDA approval and, where relevant, an interchangeability determination before automatic substitution could occur.
Why is Cathflo used instead of replacing an occluded catheter?
Cathflo can restore catheter function without a replacement procedure. The decision depends on the cause of occlusion, bleeding risk, catheter type, clinical urgency and institutional protocol.
Does Roche report Cathflo sales separately?
No. Roche public financial reports do not provide a standalone Cathflo revenue line, preventing a precise public calculation of annual product sales.
References
- U.S. Food and Drug Administration. (2022). Cathflo Activase (alteplase) prescribing information.
- Roche Holding Ltd. (2023). Annual report 2023. Basel, Switzerland: Roche.
- Roche Holding Ltd. (2024). Annual report 2024. Basel, Switzerland: Roche.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Drugs@FDA and biologics regulatory information.
